Free Trial
NASDAQ:INAB

IN8bio Q4 2024 Earnings Report

IN8bio logo
$0.18 -0.01 (-5.97%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$0.18 0.00 (-1.12%)
As of 04/28/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IN8bio EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.07
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

IN8bio's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

IN8bio Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

View IN8bio Profile

More Earnings Resources from MarketBeat